{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:26:43Z","timestamp":1761611203590},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11912-004-0048-8","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T16:23:19Z","timestamp":1180714999000},"page":"184-191","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of hepatocarcinoma"],"prefix":"10.1007","volume":"6","author":[{"given":"Beatrice","family":"Gerard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Bleiberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"48_CR1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745\u2013750.","journal-title":"N Engl J Med"},{"key":"48_CR2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<912::AID-CNCR23>3.0.CO;2-T","volume":"88","author":"WG Cance","year":"2000","unstructured":"Cance WG, Stewart AK, Menck HR: The National Cancer Data Base report on treatment patterns for hepatocellular carcinomas. Cancer 2000, 88:912\u2013992.","journal-title":"Cancer"},{"key":"48_CR3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"MH Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855\u20131859. This article demonstrates the impact of vaccination on the incidence of HCC and should encourage other countries to develop such programs.","journal-title":"N Engl J Med"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, et al.: Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517\u2013525.","journal-title":"Ann Intern Med"},{"key":"48_CR5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(98)07236-5","volume":"351","author":"Hepatocellular Carcinoma Study Group","year":"1998","unstructured":"Hepatocellular Carcinoma Study Group: Effect of interferonalfa on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study International Interferon-alfa. Lancet 1998, 351:1535\u20131539.","journal-title":"Lancet"},{"key":"48_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0168-8278(99)80196-2","volume":"30","author":"T Okanoue","year":"1999","unstructured":"Okanoue T, Itoh Y, Minami M, et al.: Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study of 1148 patients. J Hepatol 1999, 30:653\u2013659.","journal-title":"J Hepatol"},{"key":"48_CR7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Asase Y, et al.: Effects of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999, 29:1124\u20131130. This article underlines the role of preventive measure in patients with already established cirrhosis.","journal-title":"Hepatology"},{"key":"48_CR8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1440-1746.2002.02837.x","volume":"17","author":"M Matsui","year":"2002","unstructured":"Matsui M, Machida S, Itani-Yohda T, Akatsuka T: Treatment of hepatocellular carcinoma: downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-alfa. J Gastroenterol Hepatol 2002, 17:897\u2013907.","journal-title":"J Gastroenterol Hepatol"},{"key":"48_CR9","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B","volume":"79","author":"Y Arase","year":"1997","unstructured":"Arase Y, Ikeda K, Murashima N, et al.: The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79:1494\u20131500.","journal-title":"Cancer"},{"key":"48_CR10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<688::AID-CNCR5>3.0.CO;2-A","volume":"79","author":"K Tarao","year":"1997","unstructured":"Tarao K, Takemiya S, Tamai S, et al.: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997, 79:688\u2013694.","journal-title":"Cancer"},{"key":"48_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/bbrc.1995.1199","volume":"207","author":"N Nakamura","year":"1995","unstructured":"Nakamura N, Shidoji Y, Yamada Y, et al.: Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995, 207:382\u2013388.","journal-title":"Biochem Biophys Res Commun"},{"key":"48_CR12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1067\/mlc.2002.122281","volume":"139","author":"KQ Hu","year":"2002","unstructured":"Hu KQ: Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002, 139:234\u2013243.","journal-title":"J Lab Clin Med"},{"key":"48_CR13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00000658-199810000-00005","volume":"228","author":"GB Klintmalm","year":"1998","unstructured":"Klintmalm GB: Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998, 228:479\u2013490.","journal-title":"Ann Surg"},{"key":"48_CR14","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2003.11.137","volume":"21","author":"HY Yoo","year":"2003","unstructured":"Yoo HY, Patt CH, Geschwind JF, et al.: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003, 21:4329\u20134335.","journal-title":"J Clin Oncol"},{"key":"48_CR15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.sla.0000086548.84705.ef","volume":"238","author":"CH Cha","year":"2003","unstructured":"Cha CH, Ruo L, Fong Y, et al.: Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003, 238:315\u2013323.","journal-title":"Ann Surg"},{"key":"48_CR16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1053\/jhep.2000.20456","volume":"32","author":"S Arii","year":"2000","unstructured":"Arii S, Yamaoka Y, Futagawa S, et al.: Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000, 32:1224\u20131229.","journal-title":"Hepatology"},{"key":"48_CR17","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/1097-0142(20001215)89:12<2606::AID-CNCR13>3.0.CO;2-T","volume":"89","author":"Z Zhang","year":"2000","unstructured":"Zhang Z, Liu Q, He J, et al.: The effect of preoperative transcatheter hepatic arterial chemoembolization on diseasefree survival after hepatectomy for hepatocellular carcinoma. Cancer 2000, 89:2606\u20132612.","journal-title":"Cancer"},{"key":"48_CR18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/bjs.1800820141","volume":"82","author":"CC Wu","year":"1995","unstructured":"Wu CC, Ho YZ, HO WL, et al.: Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995, 82:122\u2013126.","journal-title":"Br J Surg"},{"issue":"Suppl 6","key":"48_CR19","first-page":"S18","volume":"24","author":"T Ono","year":"1997","unstructured":"Ono T, Nagasue N, Kohno H, et al.: Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomised study. Semin Oncol 1997, 24(Suppl 6):S18-S25.","journal-title":"Semin Oncol"},{"key":"48_CR20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1470-2045(02)00873-2","volume":"3","author":"JD Schwartz","year":"2002","unstructured":"Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002, 3:593\u2013603. This article points out the importance of not overtreating patients in these settings.","journal-title":"Lancet Oncol"},{"key":"48_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3748\/wjg.v9.i4.635","volume":"9","author":"H-Ch Sun","year":"2003","unstructured":"Sun H-Ch, Tang Z-Y: Preventive treatments for recurrence after curative resection of hepatocellular carcinoma: a literature review of randomised control trials. World J Gastroenterol 2003, 9:635\u2013640.","journal-title":"World J Gastroenterol"},{"key":"48_CR22","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/1097-0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2","volume":"91","author":"T Ono","year":"2001","unstructured":"Ono T, Yamanoi A, El Assal ON, et al.: Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients. Cancer 2001, 91:2378\u20132385.","journal-title":"Cancer"},{"key":"48_CR23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(98)06475-7","volume":"353","author":"W Lau","year":"1999","unstructured":"Lau W, Leung W, Ho S, et al.: Adjuvant intraarterial iodine-131-labeled Lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999, 353:797\u2013801.","journal-title":"Lancet"},{"key":"48_CR24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJM199904013401315","volume":"340","author":"Y Muto","year":"1999","unstructured":"Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999, 340:1046\u20131047.","journal-title":"N Engl J Med"},{"key":"48_CR25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/jhep.2000.9409","volume":"24","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Arase Y, Saitoh S, et al.: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomised study of hepatitis C virus-related liver cancer. Hepatology 2000, 24:228\u2013232.","journal-title":"Hepatology"},{"key":"48_CR26","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1046\/j.1440-1746.17.s4.18.x","volume":"17","author":"CJ Oon","year":"2002","unstructured":"Oon CJ: Prevention of human hepatocellular carcinoma with natural lymphoblastoid alpha interferon. J Gastroenterol Hepatol 2002, 17:S500-S501.","journal-title":"J Gastroenterol Hepatol"},{"key":"48_CR27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","volume":"356","author":"T Takayama","year":"2000","unstructured":"Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rate of HCC: a randomised trial. Lancet 2000, 356:802\u2013806.","journal-title":"Lancet"},{"key":"48_CR28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-2007-1007121","volume":"19","author":"S Okada","year":"1999","unstructured":"Okada S: Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999, 19:323\u2013328.","journal-title":"Semin Liver Dis"},{"key":"48_CR29","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/j.1572-0241.2000.03205.x","volume":"95","author":"A Orlando","year":"2000","unstructured":"Orlando A, D\u2019Antoni A, Camma C, et al.: Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol 2000, 95:2921\u20132927.","journal-title":"Am J Gastroenterol"},{"key":"48_CR30","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1682::AID-CNCR9>3.0.CO;2-6","volume":"86","author":"S Hasegawa","year":"1999","unstructured":"Hasegawa S, Yamasaki N, Hiwaki T, et al.: Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 1999, 86:1682\u20131690.","journal-title":"Cancer"},{"key":"48_CR31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.510270112","volume":"27","author":"K Onishi","year":"1998","unstructured":"Onishi K, Yoshioka H, Ito S, et al.: Prospective randomised controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998, 27:67\u201372.","journal-title":"Hepatology"},{"key":"48_CR32","first-page":"141","volume":"43","author":"JK Seifert","year":"1998","unstructured":"Seifert JK, Junginger T, Morris DL: A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998, 43:141\u2013154.","journal-title":"J R Coll Surg Edinb"},{"key":"48_CR33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00000658-199701000-00005","volume":"225","author":"R Adam","year":"1997","unstructured":"Adam R, Akpinar E, Johann M, et al.: Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 1997, 225:39\u201348.","journal-title":"Ann Surg"},{"key":"48_CR34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/sonc.2001.26951","volume":"28","author":"CC Barnett","year":"2001","unstructured":"Barnett CC, Curley SA: Ablative techniques for hepatocellular carcinoma. Semin Oncol 2001, 28:487\u2013496.","journal-title":"Semin Oncol"},{"key":"48_CR35","first-page":"126a","volume":"20","author":"M Olschewski","year":"2001","unstructured":"Olschewski M, Lencioni R, Allgaier HP, et al.: A randomised comparison of radiofrequency thermal ablation and percutaneous ethanol injection for the treatment of small hepatocellular carcinoma [abstract]. Proc ASCO 2001, 20:126a.","journal-title":"Proc ASCO"},{"key":"48_CR36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2214\/ajr.181.3.1810695","volume":"181","author":"T Ba\u00e8re De","year":"2003","unstructured":"De Ba\u00e8re T, Risse O, Kuoch V, et al.: Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003, 181:695\u2013700.","journal-title":"AJR Am J Roentgenol"},{"key":"48_CR37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/000313480206800920","volume":"68","author":"M Bloomston","year":"2002","unstructured":"Bloomston M, Binitie O, Fraiji E, et al.: Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002, 68:827\u2013831.","journal-title":"Am Surg"},{"key":"48_CR38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1051-0443(07)61792-8","volume":"13","author":"TWI Clark","year":"2002","unstructured":"Clark TWI, Soulen MC: Chemical ablation of hepatocellular carcinoma. J Vasc Radiol 2002, 13:245\u2013252.","journal-title":"J Vasc Radiol"},{"key":"48_CR39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1067\/msy.2002.122374","volume":"131","author":"PA Clavien","year":"2002","unstructured":"Clavien PA, Selzner N, Morse M, et al.: Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002, 131:433\u2013442.","journal-title":"Surgery"},{"key":"48_CR40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.1994.12.6.1204","volume":"12","author":"YZ Patt","year":"1994","unstructured":"Patt YZ, Charnsangavej C, Yoffe B, et al.: Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994, 12:1204\u20131211.","journal-title":"J Clin Oncol"},{"key":"48_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00000421-199202000-00008","volume":"15","author":"M Kajanti","year":"1992","unstructured":"Kajanti M, Pyrhonen S, Mantyla M, et al.: Intra-arterial and intravenous use of 4\u2032 epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma: a randomised comparison. Am J Clin Oncol 1992, 15:37\u201340.","journal-title":"Am J Clin Oncol"},{"key":"48_CR42","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I","volume":"88","author":"Y-H Chung","year":"2000","unstructured":"Chung Y-H, Song IH, Song B-Ch, et al.: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alfa for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000, 88:1986\u20131991.","journal-title":"Cancer"},{"key":"48_CR43","first-page":"1156","volume":"26","author":"JL Roul","year":"1997","unstructured":"Roul JL, Guyander D, Bretagne JF, et al.: Propective randomized trial of chemoembolisation versus intra-arterial iodine-131 Lipiodol in inoperable hepatocellular carcinoma. Hepatol 1997, 26:1156\u20131161.","journal-title":"Hepatol"},{"key":"48_CR44","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/cncr.11400","volume":"97","author":"MF Yuen","year":"2003","unstructured":"Yuen MF, Ooi CGC, Hui CK, et al.: A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003, 97:2776\u20132782.","journal-title":"Cancer"},{"key":"48_CR45","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1051-0443(98)70398-7","volume":"9","author":"KT Brown","year":"1998","unstructured":"Brown KT, Nevins AB, Getrajdman GI, et al.: Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998, 9:822\u2013828.","journal-title":"J Vasc Interv Radiol"},{"key":"48_CR46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","volume":"224","author":"C Camma","year":"2002","unstructured":"Camma C, Schepis F, Orlando A, et al.: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomised controlled trials. Radiology 2002, 224:47\u201354.","journal-title":"Radiology"},{"key":"48_CR47","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptom treatment in patients with unresectable hepatocellular carcinoma randomized controlled trial. Lancet 2002, 359:1734\u20131739. Recent results of well-conducted trial demonstrating the role of TACE in advanced disease.","journal-title":"Lancet"},{"key":"48_CR48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.bjc.6600116","volume":"86","author":"TJ Vogl","year":"2002","unstructured":"Vogl TJ, Engelmann K, Mack MG, et al.: CT-guided intratumoral administration of cisplatin\/epinephrine gel for treatment of malignant liver tumours. Br J Cancer 2002, 86:524\u2013529.","journal-title":"Br J Cancer"},{"key":"48_CR49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncr.10236","volume":"94","author":"TW Leung","year":"2002","unstructured":"Leung TW, Tang AM, Zee B, et al.: Factors predicting response and survival in 149 patients with unresectable HCC treated by combination cisplatin, interferon alpha, doxorubicin, and 5-fluorouracil chemotherapy. Cancer 2002, 94:421\u2013427.","journal-title":"Cancer"},{"key":"48_CR50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"Ch-M Lo","year":"2002","unstructured":"Lo Ch-M, Ngan H, Tso W-K, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164\u20131171.","journal-title":"Hepatology"},{"key":"48_CR51","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429\u2013442.","journal-title":"Hepatology"},{"key":"48_CR52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","volume":"29","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Bustamante J, Castells A, et al.: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62\u201367.","journal-title":"Hepatology"},{"key":"48_CR53","first-page":"183","volume":"50","author":"M Barone","year":"2003","unstructured":"Barone M, Ettorre GC, Ladisa R, et al.: Transcatheter arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma. Hepato-Gastroenterology 2003, 50:183\u2013187.","journal-title":"Hepato-Gastroenterology"},{"key":"48_CR54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1148\/radiology.188.1.8390073","volume":"188","author":"O Matsui","year":"1993","unstructured":"Matsui O, Kadoya M, Yoshikawa J, et al.: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993, 188:79\u201383.","journal-title":"Radiology"},{"key":"48_CR55","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1148\/radiology.197.3.7480761","volume":"197","author":"C Bartolozzi","year":"1995","unstructured":"Bartolozzi C, Lencioni R, Caramella D, et al.: Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995, 197:812\u2013818.","journal-title":"Radiology"},{"key":"48_CR56","first-page":"50","volume":"24","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Masuzawa M, Kato M, et al.: Evaluation of transcatheter arterial chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol 1997, 24:50\u201355.","journal-title":"Semin Oncol"},{"key":"48_CR57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/(SICI)1097-0215(19981218)79:6<601::AID-IJC8>3.0.CO;2-F","volume":"79","author":"HP Allgaier","year":"1998","unstructured":"Allgaier HP, Deibert P, Olschewski M, et al.: Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection: a single-center analysis including 132 patients. Int J Cancer 1998, 79:601\u2013605.","journal-title":"Int J Cancer"},{"key":"48_CR58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1148\/radiology.185.2.1329143","volume":"185","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Nakamura S, Numata K, et al.: Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 1992, 185:457\u2013460.","journal-title":"Radiology"},{"key":"48_CR59","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/1097-0142(20010915)92:6<1516::AID-CNCR1477>3.0.CO;2-I","volume":"92","author":"M Koda","year":"2001","unstructured":"Koda M, Murawaki Y, Mitsuda A, et al.: Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomised control study. Cancer 2001, 92:1516\u20131524.","journal-title":"Cancer"},{"key":"48_CR60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0360-3016(00)00462-4","volume":"47","author":"JC Cheng","year":"2000","unstructured":"Cheng JC, Chuang VP, Cheng SH, et al.: Local radiotherapy in patients with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000, 47:435\u2013442.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"48_CR61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona 2000 EASL Conference (European Association for the Study of the Liver). J Hepatol 2001, 35:421\u2013430.","journal-title":"J Hepatol"},{"key":"48_CR62","first-page":"783","volume":"48","author":"S Kubicka","year":"2001","unstructured":"Kubicka S, Rudolph KL, Tietze MK, et al.: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable. Hepato-Gastroenterology 2001, 48:783\u2013789.","journal-title":"Hepato-Gastroenterology"},{"key":"48_CR63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000058526","volume":"60","author":"H Ulrich-Pur","year":"2001","unstructured":"Ulrich-Pur H, Kornek GV, Fiebiger W, et al.: Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001, 60:313\u2013315.","journal-title":"Oncology"},{"key":"48_CR64","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.10607","volume":"94","author":"CS Fuchs","year":"2002","unstructured":"Fuchs CS, Clark JW, Ryan DP, et al.: A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002, 94:3186\u20133191.","journal-title":"Cancer"},{"key":"48_CR65","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R","volume":"89","author":"TS Yang","year":"2000","unstructured":"Yang TS, Lin YC, Chen JS, et al.: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000, 89:750\u2013756.","journal-title":"Cancer"},{"key":"48_CR66","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdf303","volume":"13","author":"TS Yang","year":"2002","unstructured":"Yang TS, Wang CH, Hsieh RK, et al.: Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 2002, 13:1771\u20131778.","journal-title":"Ann Oncol"},{"key":"48_CR67","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/annonc\/mdf079","volume":"13","author":"AB Benson III","year":"2002","unstructured":"Benson III AB, Mitchell E, Abramson N, et al.: Oral eniluracil\/ 5-fluorouracil in patients with inoperable hepatocellular carcinoma. Ann Oncol 2002, 13:576\u2013581.","journal-title":"Ann Oncol"},{"key":"48_CR68","doi-asserted-by":"crossref","unstructured":"Llovet JM, Ruff P, Tassopoulos N, et al.: A phase II trial of oral eniluracil\/5-fluorouracil in patients with inoperable hepatocellular carcinoma. Eur J Cancer 2001:1352\u20131358.","DOI":"10.1016\/S0959-8049(01)00100-9"},{"key":"48_CR69","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000012162","volume":"59","author":"M Lencioni","year":"2000","unstructured":"Lencioni M, Falcone A, Allegrini G, et al.: Oral doxifluridine in advanced hepatocellular carcinoma: a phase II study. Oncology 2000, 59:204\u2013209.","journal-title":"Oncology"},{"key":"48_CR70","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2003.10.103","volume":"21","author":"YZ Patt","year":"2003","unstructured":"Patt YZ, Hassan MM, Lozano RD, et al.: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003, 21:421\u2013427.","journal-title":"J Clin Oncol"},{"key":"48_CR71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1008386822906","volume":"11","author":"U Halm","year":"2000","unstructured":"Halm U, Etzrodt G, Schiefke I, et al.: A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000, 11:113\u2013114.","journal-title":"Ann Oncol"},{"key":"48_CR72","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-003-0583-2","volume":"51","author":"RL Hong","year":"2003","unstructured":"Hong RL, Tseng YL: A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003, 51:433\u2013438.","journal-title":"Cancer Chemother Pharmacol"},{"key":"48_CR73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bjc.1998.438","volume":"78","author":"Y Chao","year":"1998","unstructured":"Chao Y, Chan WK, Birkhofer MJ, et al.: Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998, 78:34\u201339.","journal-title":"Br J Cancer"},{"key":"48_CR74","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/1097-0142(20010101)91:1<101::AID-CNCR13>3.0.CO;2-K","volume":"91","author":"EM O\u2019Reilly","year":"2001","unstructured":"O\u2019Reilly EM, Stuart KE, Sanz-Altamira PM, et al.: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001, 91:101\u2013105.","journal-title":"Cancer"},{"key":"48_CR75","doi-asserted-by":"crossref","unstructured":"Alexandre J, Tigaud JM, Gross-Goupil M, et al.: Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002, 198\u2013203.","DOI":"10.1097\/00000421-200204000-00021"},{"key":"48_CR76","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncr.10236","volume":"94","author":"TW Leung","year":"2002","unstructured":"Leung TW, Tang AM, Zee B, et al.: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferonalpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002, 94:421\u2013427.","journal-title":"Cancer"},{"key":"48_CR77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-002-0503-x","volume":"50","author":"E Boucher","year":"2002","unstructured":"Boucher E, Corbinais S, Bissot P, et al.: Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002, 50:305\u2013308.","journal-title":"Cancer Chemother Pharmacol"},{"key":"48_CR78","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1440-1746.2000.02235.x","volume":"15","author":"Ch-K Tan","year":"2000","unstructured":"Tan Ch-K, Chow P-Kh, Findlay M, et al.: Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol Hepatol 2000, 15:725\u2013729.","journal-title":"J Gastroenterol Hepatol"},{"key":"48_CR79","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","volume":"36","author":"PKH Chow","year":"2002","unstructured":"Chow PKH, Tai B-Ch, Tan Ch-K, et al.: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomised controlled trial. Hepatology 2002, 36:1221\u20131226.","journal-title":"Hepatology"},{"key":"48_CR80","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1054\/bjoc.2000.1534","volume":"84","author":"E Villa","year":"2001","unstructured":"Villa E, Ferretti I, Grottola A, et al.: Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001, 84:881\u2013887.","journal-title":"Br J Cancer"},{"key":"48_CR81","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.1998.16.2.411","volume":"16","author":"C Grimaldi","year":"1998","unstructured":"Grimaldi C, Bleiberg H, Gay F, et al.: Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998, 16:411\u2013417.","journal-title":"J Clin Oncol"},{"key":"48_CR82","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","volume":"42","author":"E Kouroumalis","year":"1998","unstructured":"Kouroumalis E, Skordilis P, Thermos K, et al.: Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998, 42:442\u2013447.","journal-title":"Gut"},{"key":"48_CR83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00432-003-0447-5","volume":"129","author":"WD Jia","year":"2003","unstructured":"Jia WD, Xu GL, Xu RN, et al.: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003, 129:327\u2013334.","journal-title":"J Cancer Res Clin Oncol"},{"key":"48_CR84","first-page":"1245","volume":"49","author":"D Dimitroulopoulos","year":"2002","unstructured":"Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al.: The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepato-Gastroenterology 2002, 49:1245\u20131250.","journal-title":"Hepato-Gastroenterology"},{"key":"48_CR85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/jhep.2002.35071","volume":"36","author":"MF Yuen","year":"2003","unstructured":"Yuen MF, Poon RT, Lai CL, et al.: A randomised placebocontrolled study of long-acting octreotide the treatment of advanced hepatocellular carcinoma. Hepatology 2003, 36:687\u2013691.","journal-title":"Hepatology"},{"key":"48_CR86","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1054\/bjoc.2000.1716","volume":"84","author":"S Kawata","year":"2001","unstructured":"Kawata S, Yamasaki E, Nagase T, et al.: Effect of pravastatin on survival on patients with advanced hepatocellular carcinoma: a randomised controlled trial. Br J Cancer 2001, 84:886\u2013891.","journal-title":"Br J Cancer"},{"key":"48_CR87","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00000421-200206000-00003","volume":"25","author":"G Palmieri","year":"2002","unstructured":"Palmieri G, Monella L, Milo M, et al.: Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol 2002, 25:224\u2013226.","journal-title":"Am J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-004-0048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-004-0048-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-004-0048-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:08:48Z","timestamp":1683864528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-004-0048-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1007\/s11912-004-0048-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}